3 курс / Фармакология / Интеллектуальные_липидные_наноконтейнеры_в_адресной_доставке_лекарственных

219

239.Perlin D.S. (2004) Amphotericin B cochleates: a vehicle for oral delivery.

Curr.Opin.Investig.Drugs, 5, 198-201.

240.Delmas G., Park S., Chen Z.W., Tan F., Kashiwazaki R., Zarif L., Perlin D.S. (2002) Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob.Agents Chemother., 46, 2704-2707.

241.Rao R., Squillante E., III, Kim K.H. (2007) Lipid-based cochleates: a promising formulation platform for oral and parenteral delivery of therapeutic agents. Crit Rev.Ther.Drug Carrier Syst., 24, 41-61.

242.Caboi F., Amico G.S., Pitzalis P., Monduzzi M., Nylander T., Larsson K. (2001) Addition of hydrophilic and lipophilic compounds of biological relevance to the monoolein/water system. I. Phase behavior. Chem.Phys.Lipids, 109, 47-62.

243.Helledi L.S., Schubert L. (2001) Release kinetics of acyclovir from a suspension of acyclovir incorporated in a cubic phase delivery system. Drug Dev.Ind.Pharm., 27, 10731081.

244.Chang C.M., Bodmeier R. (1997) Swelling of and drug release from monoglyceridebased drug delivery systems. J.Pharm.Sci., 86, 747-752.

245.Chang C.M., Bodmeier R. (1997) Effect of dissolution media and additives on the drug release from cubic phase delivery systems. J.Controled Release, 46, 197-289.

246.Sawant K.K., Dodiya S.S. (2008) Recent advances and patents on solid lipid nanoparticles. Recent Pat Drug Deliv.Formul., 2, 120-135.

247.Uner M. (2006) Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie, 61, 375-386.

248.Wong H.L., Bendayan R., Rauth A.M., Li Y., Wu X.Y. (2007) Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv.Drug Deliv.Rev., 59, 491-504.

249.Brioschi A., Zara G.P., Calderoni S., Gasco M.R., Mauro A. (2008) Cholesterylbutyrate solid lipid nanoparticles as a butyric acid prodrug. Molecules., 13, 230-254.

250.Almeida A.J., Souto E. (2007) Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv.Drug Deliv.Rev., 59, 478-490.

251.Bummer P.M. (2004) Physical chemical considerations of lipid-based oral drug delivery – solid lipid nanoparticles . Crit Rev.Ther.Drug Carrier Syst., 21, 1-20.

252.Muller R.H., Radtke M., Wissing S.A. (2002) Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv.Drug Deliv.Rev., 54, S131-S155.

253.Wissing S.A., Kayser O., Muller R.H. (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv.Drug Deliv.Rev., 56, 1257-1272.

254.Blasi P., Giovagnoli S., Schoubben A., Ricci M., Rossi C. (2007) Solid lipid nanoparticles for targeted brain drug delivery. Adv.Drug Deliv.Rev., 59, 454-477.

255.Kaur I.P., Bhandari R., Bhandari S., Kakkar V. (2008) Potential of solid lipid nanoparticles in brain targeting. J.Control Release, 127, 97-109.

256.Debbage P. (2009) Targeted drugs and nanomedicine: present and future.

Curr.Pharm.Des, 15, 153-172.

257.Jensen G.M., Bunch T.H. (2007) Conventional liposome performance and evaluation: lessons from the development of Vescan. J.Liposome Res., 17, 121-137.

258.Marcato P.D., Duran N. (2008) New aspects of nanopharmaceutical delivery systems.

J.Nanosci.Nanotechnol., 8, 2216-2229.

259.Samad A., Sultana Y., Aqil M. (2007) Liposomal drug delivery systems: an update review. Curr.Drug Deliv., 4, 297-305.

260.Engstrom S., Norden T.P., Nyquist H. (1999) Cubic phases for studies of drug partition into lipid bilayers. Eur.J.Pharm.Sci., 8, 243-254.

261.Barauskas J., Landh T. (2003) Phase Behavior of the Phytantriol/Water System. Langmuir, 19, 9562-9565.

262.Barauskas J., Svedaite I., Butkus E., Razumas V., Larsson K., Tiberg F. (2005) Synthesis and aqueous phase behavior of 1-glyceryl monooleyl ether. Colloids Surf.B Biointerfaces., 41, 49-53.

263.Clogston J., Caffrey M. (2005) Controlling release from the lipidic cubic phase. Amino acids, peptides, proteins and nucleic acids. J.Control Release, 107, 97-111.

220

264.Shah J.C., Sadhale Y., Chilukuri D.M. (2001) Cubic phase gels as drug delivery systems. Adv.Drug Deliv.Rev., 47, 229-250.

265.Yang D., Armitage B., Marder S.R. (2004) Cubic liquid-crystalline nanoparticles.

Angew.Chem.Int.Ed Engl., 43, 4402-4409.

266.Barauskas J., Johnsson M., Joabsson F., Tiberg F. (2005) Cubic phase nanoparticles (Cubosome): principles for controlling size, structure, and stability. Langmuir, 21, 2569-2577.

267.Barauskas J., Johnsson M., Tiberg F. (2005) Self-assembled lipid superstructures: beyond vesicles and liposomes. Nano.Lett., 5, 1615-1619.

268.Barauskas J., Razumas V., Nylander T. (2000) Entrapment of glucose oxidase into the cubic Q230 and Q224 phases of aqueous monoolein. Prog.Coll.Polym.Sci., 116, 16-20.

269.Sadhale Y., Shah J.C. (1998) Glyceryl monooleate cubic phase gel as chemical stability enhancer of cefazolin and cefuroxime. Pharm.Dev.Technol., 3, 549-556.

270.Sadhale Y., Shah J.C. (1999) Stabilization of insulin against agitation-induced aggregation by the GMO cubic phase gel. Int.J.Pharm., 191, 51-64.

271.Briggs J., Caffrey M. (1994) The temperature-composition phase diagram of monomyristolein in water: equilibrium and metastability aspects. Biophys.J., 66, 573-587.

272.Briggs J., Caffrey M. (1994) The temperature-composition phase diagram and mesophase structure characterization of monopentadecenoin in water. Biophys.J., 67, 15941602.

273.Misquitta Y., Caffrey M. (2001) Rational design of lipid molecular structure: a case study involving the C19:1c10 monoacylglycerol. Biophys.J., 81, 1047-1058.

274.Misquitta Y., Cherezov V., Havas F., Patterson S., Mohan J.M., Wells A.J., Hart D.J., Caffrey M. (2004) Rational design of lipid for membrane protein crystallization.

J.Struct.Biol., 148, 169-175.

275.Qiu H., Caffrey M. (1999) Phase behavior of the monoerucin/water system.

Chem.Phys.Lipids, 100, 55-79.

276.Qiu H., Caffrey M. (2000) The phase diagram of the monoolein/water system: metastability and equilibrium aspects. Biomaterials, 21, 223-234.

277.Lutton E.S. (1965) Phase behavior of aqueous systems of monoglycerides. J.Am.Oil Chem.Soc., 42, 1068-1070.

278.Larsson K., Gabrielsson K., Lundberg J. (1978) Phase behaviour of some aqueous systems involving monoglycerides, cholesterol and bile acids. J.Sci.Food Agric., 29, 909-914.

279.Caffrey M. (1989) A lyotrope gradient method for liquid crystal temperature- composition-mesomorph diagram construction using time-resolved x-ray diffraction.

Biophys.J., 55, 47-52.

280.Boyd B.J., Whittaker D.V., Khoo S.M., Davey G. (2006) Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems. Int.J.Pharm., 309, 218-226.

281.Hato M., Minamikawa H., Tamada K., Baba T., Tanabe Y. (1999) Self-assembly of synthetic glycolipid/water systems. Adv.Colloid Interface Sci., 80, 233-270.

282.Salkar R.A., Minamikawa H., Hato M. (2004) Alkylglucosides with isoprenoid-type hydrophobic chains-effects of hydrophobic chain size on the aqueous phase behavior.

Chem.Phys.Lipids, 127, 65-75.

283.Hato M., Yamashita I., Kato T., Abe Y. (2004) Aqueous phase behavior of a 1-O- phytanyl-beta-D-xyloside/water system. Glycolipid-based bicontinuous cubic phases of crystallographic space groups Pn3m and Ia3d. Langmuir, 20, 11366-11373.

284.von Minden H.M., Morr M., Milkereit G., Heinz E., Vill V. (2002) Synthesis and mesogenic properties of glycosyl diacylglycerols. Chem.Phys.Lipids, 114, 55-80.

285.Misquitta L.V., Misquitta Y., Cherezov V., Slattery O., Mohan J.M., Hart D., Zhalnina M., Cramer W.A., Caffrey M. (2004) Membrane protein crystallization in lipidic mesophases with tailored bilayers. Structure., 12, 2113-2124.

286.Qiu H., Caffrey M. (1998) Lyotropic and thermotropic phase behavior of hydrated monoacylglycerols: structure characterization of monovaccenin. J.Phys.Chem., 102, 48194829.

287.Angelov B., Angelova A., Ollivon M., Bourgaux C., Campitelli A. (2003) Diamondtype lipid cubic phase with large water channels. J.Am.Chem.Soc., 125, 7188-7189.

221

288.Briggs J., Chung H., Caffrey M. (1996) The Temperature-Composition Phase Diagram and Mesophase Structure Characterization of the Monoolein/Water System. J.Phys.II, 6, 723-

289.Barauskas J., Misiunas A., Gunnarsson T., Tiberg F., Johnsson M. (2006) "Sponge" nanoparticle dispersions in aqueous mixtures of diglycerol monooleate, glycerol dioleate, and polysorbate 80. Langmuir, 22, 6328-6334.

290.Li S.J., Yamashita Y., Yamazaki M. (2001) Effect of electrostatic interactions on phase stability of cubic phases of membranes of monoolein/dioleoylphosphatidic acid mixtures. Biophys.J., 81, 983-993.

291.Yaghmur A., de Campo L., Sagalowicz L., Leser M.E., Glatter O. (2006) Control of the internal structure of MLO-based isasomes by the addition of diglycerol monooleate and soybean phosphatidylcholine. Langmuir, 22, 9919-9927.

292.Efrat R., Aserin A., Garti N. (2008) On structural transitions in a discontinuous micellar cubic phase loaded with sodium diclofenac. J.Colloid Interface Sci., 321, 166-176.

293.Efrat R., Shalev D.E., Hoffman R.E., Aserin A., Garti N. (2008) Effect of sodium diclofenac loads on mesophase components and structure. Langmuir, 24, 7590-7595.

294.Kumar M.K., Shah M.H., Ketkar A., Mahadik K.R., Paradkar A. (2004) Effect of drug solubility and different excipients on floating behaviour and release from glyceryl monooleate matrices. Int.J.Pharm., 272, 151-160.

295.Welin-Berger K., Neelissen J.A., Engblom J. (2002) Physicochemical interaction of local anesthetics with lipid model systems – correl ation with in vitro permeation and in vivo efficacy. J.Control Release, 81, 33-43.

296.Efrat R., Kesselman E., Aserin A., Garti N., Danino D. (2009) Solubilization of hydrophobic guest molecules in the monoolein discontinuous QL cubic mesophase and its soft nanoparticles. Langmuir, 25, 1376-1326.

297.Boyd B.J. (2003) Characterisation of drug release from cubosomes using the pressure ultrafiltration method. Int.J.Pharm., 260, 239-247.

298.Rosa M., Rosa I.M., Miguel M.G., Lindman B. (2006) Spontaneous formation of vesicles and dispersed cubic and hexagonal particles in amino acid-based catanionic surfactant systems. Langmuir, 22, 5588-5596.

299.Spicer P.T., Hayden K.L., Lynch M.L., Ofiri-Broateng A., Burns J.L. (2009) Novel process for producing cubic liquid crystalline nanoparticles (cubosomes). Langmuir, 17, 5748-5756.

300.Nakano M., Sugita A., Matsuoka H., Handa T. (2001) Small-angle X-ray scattering and 13C NMR investigation of the internal structure of “cubosomes”. Langmuir, 17, 39173922.

301.Efrat R., Aserin A., Kesselman E., Danino D., Wachtel E.J., Gafti N. (2007) Liquid micellar discontinuous cubic mesophase from ternary monoolein/ethanol/water mixtures.

Colloids Surf.A Physicochem.Eng.Aspects., 299, 133-145.

302.Chung H., Jeong S.Y., Kwon I.C., (2005) Cubic liquid-crystalline particles as protein and insoluble drug delivery systems. "Bicontinuous liquid crystals" Lynch L.M., Spicer P.T. Boca Raton, London, New York, Singapore: Taylor&Francis Group, LLC CRC Press; 353-

303.Sallam A.S., Khalil E., Ibrahim H., Freij I. (2002) Formulation of an oral dosage form utilizing the properties of cubic liquid crystalline phases of glyceryl monooleate.

Eur.J.Pharm.Biopharm., 53, 343-352.

304.Ganem-Quintanar A., Quintanar-Guerrero D., Buri P. (2000) Monoolein: a review of the pharmaceutical applications. Drug Dev.Ind.Pharm., 26, 809-820.

305.Lee J., Kellaway I.W., (2005) The controlled release of drugs from cubic phases of glycerol monooleate. "Bicontinuous liquid crystals" Lynch L.M., Spicer P.T. Boca Raton, London, New York, Singapore: Taylor&Francis Group, LLC CRC Press; 457-469.

306.Guan L., Mirza O., Verner G., Iwata S., Kaback H.R. (2007) Structural determination of wild-type lactose permease. Proc.Natl.Acad.Sci.U.S.A, 104, 15294-15298.

307.Kurisu G., Zhang H., Smith J.L., Cramer W.A. (2003) Structure of the cytochrome b6f complex of oxygenic photosynthesis: tuning the cavity. Science, 302, 1009-1014.

222

308.Nollert P., Qiu H., Caffrey M., Rosenbusch J.P., Landau E.M. (2001) Molecular mechanism for the crystallization of bacteriorhodopsin in lipidic cubic phases. FEBS Lett., 504, 179-186.

309.Pebay-Peyroula E., Rummel G., Rosenbusch J.P., Landau E.M. (1997) X-ray structure of bacteriorhodopsin at 2.5 angstroms from microcrystals grown in lipidic cubic phases. Science, 277, 1676-1681.

310.Belrhali H., Nollert P., Royant A., Menzel C., Rosenbusch J.P., Landau E.M., PebayPeyroula E. (1999) Protein, lipid and water organization in bacteriorhodopsin crystals: a molecular view of the purple membrane at 1.9 A resolution. Structure., 7, 909-917.

311.Kolbe M., Besir H., Essen L.O., Oesterhelt D. (2000) Structure of the light-driven chloride pump halorhodopsin at 1.8 A resolution. Science, 288, 1390-1396.

312.Gordeliy V.I., Labahn J., Moukhametzianov R., Efremov R., Granzin J., Schlesinger R., Buldt G., Savopol T., Scheidig A.J., Klare J.P., Engelhard M. (2002) Molecular basis of transmembrane signalling by sensory rhodopsin II-transducer complex. Nature, 419, 484-487.

313.Royant A., Nollert P., Edman K., Neutze R., Landau E.M., Pebay-Peyroula E., Navarro J. (2001) X-ray structure of sensory rhodopsin II at 2.1-A resolution.

Proc.Natl.Acad.Sci.U.S.A, 98, 10131-10136.

314.Vogeley L., Sineshchekov O.A., Trivedi V.D., Sasaki J., Spudich J.L., Luecke H. (2004) Anabaena sensory rhodopsin: a photochromic color sensor at 2.0 A. Science, 306, 1390-1393.

315.Chiu M.L., Nollert P., Loewen M.C., Belrhali H., Pebay-Peyroula E., Rosenbusch J.P., Landau E.M. (2000) Crystallization in cubo: general applicability to membrane proteins. Acta Crystallogr. D. Biol.Crystallogr., 56, 781-784.

316.Katona G., Andreasson U., Landau E.M., Andreasson L.E., Neutze R. (2003) Lipidic cubic phase crystal structure of the photosynthetic reaction centre from Rhodobacter sphaeroides at 2.35A resolution. J.Mol.Biol., 331, 681-692.

317.Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., Choi H.J., Kuhn P., Weis W.I., Kobilka B.K., Stevens R.C. (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science, 318, 1258-1265.

318.Rosenbaum D.M., Cherezov V., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., Choi H.J., Yao X.J., Weis W.I., Stevens R.C., Kobilka B.K. (2007) GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science, 318, 1266-1273.

319.Portmann M., Nandau E.M., Luisi P.L. (1991) Spectroscopic and rheological studies of enzymes in rigid lipidic matrices: the case of α-chymotrypsin in a lysolecithin/water cubic phase. J.Phys.Chem., 95, 8437-8440.

320.Landau E.M., Luisi P.L. (1993) Lipidic cubic phases as transparent, rigid matrixes for the direct spectroscopic study of immobilized membrane proteins. J.Am.Chem.Soc., 115, 2102-2106.

321.Hochkoeppler A., Landau E.M., Venturoli G., Zannoni D., Feick R., Luisi P.L. (1995) Photochemistry of a photosynthetic reaction center immobilized in lipidic cubic phases.

Biotechnol.Bioeng., 46, 93-98.

322.Nollert P., Landau E.M. (1998) Enzymic release of crystals from lipidic cubic phases.

Biochem.Soc.Trans., 26, 709-713.

323.Wohri A.B., Johansson L.C., Wadsten-Hindrichsen P., Wahlgren W.Y., Fischer G., Horsefield R., Katona G., Nyblom M., Oberg F., Young G., Cogdell R.J., Fraser N.J., Engstrom S., Neutze R. (2008) A lipidic-sponge phase screen for membrane protein crystallization. Structure., 16, 1003-1009.

324.Wadsten P., Wohri A.B., Snijder A., Katona G., Gardiner A.T., Cogdell R.J., Neutze R., Engstrom S. (2006) Lipidic sponge phase crystallization of membrane proteins.

J.Mol.Biol., 364, 44-53.

325.Cherezov V., Clogston J., Papiz M.Z., Caffrey M. (2006) Room to move: crystallizing membrane proteins in swollen lipidic mesophases. J.Mol.Biol., 357, 1605-1618.

326.Cherezov V., Yamashita E., Liu W., Zhalnina M., Cramer W.A., Caffrey M. (2006) In meso structure of the cobalamin transporter, BtuB, at 1.95 A resolution. J.Mol.Biol., 364, 716-

223

327.Muller R.H., Mehnert W., Lucks J.S., Schwarz C., Muhlen Z., Weihers H., Freitas C., Ruhl D. (1995) Solid lipid nanoparticles (SLN) – an alternative colloidal carrier system for control drug delivery. Eur.J.Pharm.Biopharm., 41, 62-69.

328.Bhaskar K., Anbu J., Ravichandiran V., Venkateswarlu V., Rao Y.M. (2009) Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis., 8, 6-20.

329.Joshi M.D., Muller R.H. (2009) Lipid nanoparticles for parenteral delivery of actives.

Eur.J.Pharm.Biopharm., 71, 161-172.

330.Muller R.H., Petersen R.D., Hommoss A., Pardeike J. (2007) Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv.Drug Deliv.Rev., 59, 522-530.

331.Doktorovova S., Souto E.B. (2009) Nanostructured lipid carrier-based hydrogel formulations for drug delivery: a comprehensive review. Expert.Opin.Drug Deliv., 6, 165-

332.Mukherjee S., Ray S., Thakur R.S. (2009) Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J.Pharm.Sci., 73, 349-358.

333.Muchow M., Maincent P., Muller R.H. (2008) Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev.Ind.Pharm., 34, 1394-1405.

334.Iddings D., Bilchik A. (2007) The biologic significance of micrometastatic disease and sentinel lymph node technology on colorectal cancer. J.Surg.Oncol., 96, 671-677.

335.Pardeike J., Hommoss A., Muller R.H. (2009) Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int.J.Pharm., 366, 170-184.

336.Weyenberg W., Filev P., Van den P.D., Vandervoort J., De Smet K., Sollie P., Ludwig A. (2007) Cytotoxicity of submicron emulsions and solid lipid nanoparticles for dermal application. Int.J.Pharm., 337, 291-298.

337.Nassimi M., Schleh C., Lauenstein H.D., Hussein R., Hoymann H.G., Koch W., Pohlmann G., Krug N., Sewald K., Rittinghausen S., Braun A., Muller-Goymann C. (2010) A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur.J.Pharm.Biopharm., 75, 107-116.

338.Nassimi M., Schleh C., Lauenstein H.D., Hussein R., Lubbers K., Pohlmann G., Switalla S., Sewald K., Muller M., Krug N., Muller-Goymann C.C., Braun A. (2009) Low cytotoxicity of solid lipid nanoparticles in in vitro and ex vivo lung models. Inhal.Toxicol., 21, 104-109.

339.Gokce E.H., Sandri G., Egrilmez S., Bonferoni M.C., Guneri T., Caramella C. (2009)

Cyclosporine a – loaded solid lipid nanoparticles: ocular toler ance and in vivo drug release in rabbit eyes. Curr.Eye Res., 34, 996-1003.

340.Araujo J., Gonzalez E., Egea M.A., Garcia M.L., Souto E.B. (2009) Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomedicine., 5, 394-401.

341.Kaur I.P., Rana C., Singh H. (2008) Development of effective ocular preparations of antifungal agents. J.Ocul.Pharmacol.Ther., 24, 481-493.

342.Dong X., Mattingly C.A., Tseng M., Cho M., Adams V.R., Mumper R.J. (2009) Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization. Eur.J.Pharm.Biopharm., 72, 9-17.

343.Lee M.K., Lim S.J., Kim C.K. (2007) Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials, 28, 2137-2146.

344.Serpe L., Catalano M.G., Cavalli R., Ugazio E., Bosco O., Canaparo R., Muntoni E., Frairia R., Gasco M.R., Eandi M., Zara G.P. (2004) Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line.

Eur.J.Pharm.Biopharm., 58, 673-680.

345.Yuan H., Miao J., Du Y.Z., You J., Hu F.Q., Zeng S. (2008) Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int.J.Pharm., 348, 137-145.

346.Shenoy V.S., Gude R.P., Ramchandra Murthy R.S. (2009) Paclitaxel-loaded glyceryl palmitostearate nanoparticles: in vitro release and cytotoxic activity. J.Drug Target 1-7.

347.Shenoy V.S., Rajyaguru T.H., Gude R.P., Murthy R.S. (2009) Studies on paclitaxelloaded glyceryl monostearate nanoparticles. J.Microencapsul., 26, 471-478.

224

348.Chen D.B., Yang T.Z., Lu W.L., Zhang Q. (2001) In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel.

Chem.Pharm.Bull.(Tokyo), 49, 1444-1447.

349.Pandita D., Ahuja A., Velpandian T., Lather V., Dutta T., Khar R.K. (2009) Characterization and in vitro assessment of paclitaxel loaded lipid nanoparticles formulated using modified solvent injection technique. Pharmazie, 64, 301-310.

350.Li X., Nie S.F., Kong J., Li N., Ju C.Y., Pan W.S. (2008) A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int.J.Pharm., 363, 177-

351.Han F., Li S., Yin R., Shi X., Jia Q. (2008) Investigation of nanostructured lipid carriers for transdermal delivery of flurbiprofen. Drug Dev.Ind.Pharm., 34, 453-458.

352.Teeranachaideekul V., Souto E.B., Junyaprasert V.B., Muller R.H. (2007) Cetyl palmitate-based NLC for topical delivery of Coenzyme Q(10) - development, physicochemical characterization and in vitro release studies. Eur.J.Pharm.Biopharm., 67, 141-148.

353.Yuan H., Wang L.L., Du Y.Z., You J., Hu F.Q., Zeng S. (2007) Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by meltemulsification. Colloids Surf.B Biointerfaces., 60, 174-179.

354.Zhang X.G., Miao J., Dai Y.Q., Du Y.Z., Yuan H., Hu F.Q. (2008) Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int.J.Pharm., 361, 239-244.

355.Fang J.Y., Fang C.L., Liu C.H., Su Y.H. (2008) Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur.J.Pharm.Biopharm., 70, 633-640.

356.Khan A.Y., Talegaonkar S., Iqbal Z., Ahmed F.J., Khar R.K. (2006) Multiple emulsions: an overview. Curr.Drug Deliv., 3, 429-443.

357.Tamilvanan S. (2004) Oil-in-water lipid emulsions: implications for parenteral and ocular delivering systems. Prog.Lipid Res., 43, 489-533.

358.Olbrich C., Gessner A., Schroder W., Kayser O., Muller R.H. (2004) Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene-cytotoxicity testing and mouse serum adsorption. J.Control Release, 96, 425-435.

359.Olbrich C., Gessner A., Kayser O., Muller R.H. (2002) Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J.Drug Target, 10, 387-396.

360.Date A.A., Joshi M.D., Patravale V.B. (2007) Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv.Drug Deliv.Rev., 59, 505-521.

361.Unger M., Wissing S.A., Yener G., Muller R.H. (2005) Skin moisturizing effect and skin penetration of ascorbic palmitate entrapped in solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) incorporated into hydrogel. Pharmazie, 60, 751-755.

362.Unger M., Wissing S.A., Yener G., Muller R.H. (2005) Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for application of ascorbyl palmitate. Pharmazie, 60, 577-582.

363.Wang D., Zhao P., Zhang C., Zhang R., Li X., Cui F. (2006) Preparation and characterization of total flavones of Hippophae rhamnoides (TFH) solid lipid nanoparticles by heating-ultasonic dispersion and lyophilization. Asian J.Pharm.Aci., 1, 205-212.

364.Esposito E., Fantin M., Marti M., Drechsler M., Paccamiccio L., Mariani P., Sivieri E., Lain F., Menegatti E., Morari M., Cortesi R. (2008) Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm.Res., 25, 1521-1530.

365.Pople P.V., Singh K.K. (2006) Development and evaluation of topical formulation containing solid lipid nanoparticles of vitamin A. AAPS.PharmSciTech., 7, 91-97.

366.Lu B., Xiong S.B., Yang H., Yin X.D., Chao R.B. (2006) Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases.

Eur.J.Pharm.Sci., 28, 86-95.

367.Wong H.L., Chattopadhyay N., Wu X.Y., Bendayan R. (2010) Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv.Drug Deliv.Rev., 62, 503-517.

225

368.Denora N., Trapani A., Laquintana V., Lopedota A., Trapani G. (2009) Recent advances in medicinal chemistry and pharmaceutical technology – strategies for drug delivery to the brain. Curr.Top.Med.Chem., 9, 182-196.

369.Souto E.B., Muller R.H. (2006) The use of SLN and NLC as topical particulate carriers for imidazole antifungal agents. Pharmazie, 61, 431-437.

370.Souto E.B., Mehnert W., Muller R.H. (2006) Polymorphic behaviour of Compritol888 ATO as bulk lipid and as SLN and NLC. J.Microencapsul., 23, 417-433.

371.Jain S.K., Chourasia M.K., Masuriha R., Soni V., Jain A., Jain N.K., Gupta Y. (2005) Solid lipid nanoparticles bearing flurbiprofen for transdermal delivery. Drug Deliv., 12, 207-

372.Liu W., Hu M., Liu W., Xue C., Xu H., Yang X. (2008) Investigation of the carbopol gel of solid lipid nanoparticles for the transdermal iontophoretic delivery of triamcinolone acetonide acetate. Int.J.Pharm., 364, 135-141.

373.Kalariya M., Padhi B.K., Chougule M., Misra A. (2005) Clobetasol propionate solid lipid nanoparticles cream for effective treatment of eczema: formulation and clinical implications. Indian J.Exp.Biol., 43, 233-240.

374.Sivaramakrishnan R., Nakamura C., Mehnert W., Korting H.C., Kramer K.D., SchaferKorting M. (2004) Glucocorticoid entrapment into lipid carriers – characterisation by parelectric spectroscopy and influence on dermal uptake. J.Control Release, 97, 493-502.

375.Chen H., Chang X., Du D., Liu W., Liu J., Weng T., Yang Y., Xu H., Yang X. (2006) Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J.Control Release, 110, 296-306.

376.Jenning V., Schafer-Korting M., Gohla S. (2000) Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J.Control Release, 66, 115-126.

377.Liu J., Hu W., Chen H., Ni Q., Xu H., Yang X. (2007) Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int.J.Pharm., 328, 191-195.

378.Choi M.J., Kim J.H., Maibach H.I. (2006) Topical DNA vaccination with DNA/Lipid based complex. Curr.Drug Deliv., 3, 37-45.

379.Joshi M., Patravale V. (2006) Formulation and evaluation of Nanostructured Lipid Carrier (NLC)-based gel of Valdecoxib. Drug Dev.Ind.Pharm., 32, 911-918.

380.Shen J., Sun M., Ping Q., Ying Z., Liu W. (2010) Incorporation of liquid lipid in lipid nanoparticles for ocular drug delivery enhancement. Nanotechnology., 21, 025101.

381.Basaran E., Demirel M., Sirmagul B., Yazan Y. (2009) Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J.Microencapsul.

382.Attama A.A., Reichl S., Muller-Goymann C.C. (2009) Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea. Curr.Eye Res., 34, 698-705.

383.Kalam M.A., Sultana Y., Ali A., Aqil M., Mishra A.K., Chuttani K. (2010) Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system. J.Drug Target, 18, 191-204.

384.Cavalli R., Gasco M.R., Chetoni P., Burgalassi S., Saettone M.F. (2002) Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int.J.Pharm., 238, 241-245.

385.Liu J., Gong T., Fu H., Wang C., Wang X., Chen Q., Zhang Q., He Q., Zhang Z. (2008) Solid lipid nanoparticles for pulmonary delivery of insulin. Int.J.Pharm., 356, 333-

386.Xiang Q.Y., Wang M.T., Chen F., Gong T., Jian Y.L., Zhang Z.R., Huang Y. (2007) Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles.

Arch.Pharm.Res., 30, 519-525.

387.Kang K.W., Chun M.K., Kim O., Subedi R.K., Ahn S.G., Yoon J.H., Choi H.K. (2010) Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomedicine., 6, 210-213.

388.Zhu R.R., Qin L.L., Wang M., Wu S.M., Wang S.L., Zhang R., Liu Z.X., Sun X.Y., Yao S.D. (2009) Preparation, characterization, and anti-tumor property of podophyllotoxinloaded solid lipid nanoparticles. Nanotechnology., 20, 055702.

389.Sharma P., Ganta S., Denny W.A., Garg S. (2009) Formulation and pharmacokinetics of lipid nanoparticles of a chemically sensitive nitrogen mustard derivative: Chlorambucil. Int.J.Pharm., 367, 187-194.

226

390.Xu Z., Chen L., Gu W., Gao Y., Lin L., Zhang Z., Xi Y., Li Y. (2009) The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma.

Biomaterials, 30, 226-232.

391.Goutayer M., Dufort S., Josserand V., Royere A., Heinrich E., Vinet F., Bibette J., Coll J.L., Texier I. (2010) Tumor targeting of functionalized lipid nanoparticles: Assessment by in vivo fluorescence imaging. Eur.J.Pharm.Biopharm., 75, 137-147.

392.Zhang Z., Chen J., Ding L., Jin H., Lovell J.F., Corbin I.R., Cao W., Lo P.C., Yang M., Tsao M.S., Luo Q., Zheng G. (2010) HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small, 6, 430-437.

393.Wu L., Tang C., Yin C. (2010) Folate-mediated solid-liquid lipid nanoparticles for paclitaxel-coated poly(ethylene glycol). Drug Dev.Ind.Pharm., 36, 439-448.

394.Wei W., Shi S.J., Liu J., Sun X., Ren K., Zhao D., Zhang X.N., Zhang Z.R., Gong T. (2010) Lipid nanoparticles loaded with 10-hydroxycamptothecin-phospholipid complex developed for the treatment of hepatoma in clinical application. J.Drug Target.

395.Ali H., Shirode A.B., Sylvester P.W., Nazzal S. (2010) Preparation, characterization, and anticancer effects of simvastatin-tocotrienol lipid nanoparticles. Int.J.Pharm., 389, 223-

396.Hayes M.E., Drummond D.C., Kirpotin D.B., Zheng W.W., Noble C.O., Park J.W., Marks J.D., Benz C.C., Hong K. (2006) Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene Ther., 13, 646-651.

397.Pedersen N., Hansen S., Heydenreich A.V., Kristensen H.G., Poulsen H.S. (2006) Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands.

Eur.J.Pharm.Biopharm., 62, 155-162.

398.Hayes M.E., Drummond D.C., Hong K., Park J.W., Marks J.D., Kirpotin D.B. (2006) Assembly of nucleic acid-lipid nanoparticles from aqueous-organic monophases. Biochim.Biophys.Acta, 1758, 429-442.

399.Hayes M.E., Drummond D.C., Hong K., Zheng W.W., Khorosheva V.A., Cohen J.A., C O N 4th, Park J.W., Marks J.D., Benz C.C., Kirpotin D.B. (2006) Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation. Mol.Pharm., 3, 726-736.

400.Friedmann T., Roblin R. (1972) Gene therapy for human genetic disease? Science, 175, 949-955.

401.Check E. (2005) Gene therapy put on hold as third child develops cancer. Nature, 433,

402.Li Z., Dullmann J., Schiedlmeier B., Schmidt M., von Kalle C., Meyer J., Forster M., Stocking C., Wahlers A., Frank O., Ostertag W., Kuhlcke K., Eckert H.G., Fehse B., Baum C. (2002) Murine leukemia induced by retroviral gene marking. Science, 296, 497.

403.Marshall E. (2002) Clinical research. Gene therapy a suspect in leukemia-like disease. Science, 298, 34-35.

404.Schroder A.R., Shinn P., Chen H., Berry C., Ecker J.R., Bushman F. (2002) HIV-1 integration in the human genome favors active genes and local hotspots. Cell, 110, 521-529.

405.Woods N.B., Muessig A., Schmidt M., Flygare J., Olsson K., Salmon P., Trono D., von Kalle C., Karlsson S. (2003) Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. Blood, 101, 1284-1289.

406.Kaiser J. (2007) Clinical research. Death prompts a review of gene therapy vector. Science, 317, 580.

407.Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz M., Northrop J.P., Ringold G.M., Danielsen M. (1987) Lipofection: a highly efficient, lipid-mediated DNAtransfection procedure. Proc.Natl.Acad.Sci.U.S.A, 84, 7413-7417.

408.Felgner P.L., Ringold G.M. (1989) Cationic liposome-mediated transfection. Nature, 337, 387-388.

409.Edelstein M.L., Abedi M.R., Wixon J. (2007) Gene therapy clinical trials worldwide to 2007 – an update . J.Gene Med., 9, 833-842.

410.Alexander B.L., Ali R.R., Alton E.W., Bainbridge J.W., Braun S., Cheng S.H., Flotte T.R., Gaspar H.B., Grez M., Griesenbach U., Kaplitt M.G., Ott M.G., Seger R., Simons M.,

227

Thrasher A.J., Thrasher A.Z., Yla-Herttuala S. (2007) Progress and prospects: gene therapy clinical trials (part 1). Gene Ther., 14, 1439-1447.

411.Aiuti A., Bachoud-Levi A.C., Blesch A., Brenner M.K., Cattaneo F., Chiocca E.A., Gao G., High K.A., Leen A.M., Lemoine N.R., McNeish I.A., Meneguzzi G., Peschanski M., Roncarolo M.G., Strayer D.S., Tuszynski M.H., Waxman D.J., Wilson J.M. (2007) Progress and prospects: gene therapy clinical trials (part 2). Gene Ther., 14, 1555-1563.

412.Zuhorn I.S., Engberts J.B., Hoekstra D. (2007) Gene delivery by cationic lipid vectors: overcoming cellular barriers. Eur.Biophys.J., 36, 349-362.

413.Moghimi S.M., Hunter A.C., Murray J.C. (2005) Nanomedicine: current status and future prospects. FASEB J., 19, 311-330.

414.Curiel D.T., Agarwal S., Wagner E., Cotten M. (1991) Adenovirus enhancement of transferrin-polylysine-mediated gene delivery. Proc.Natl.Acad.Sci.U.S.A, 88, 8850-8854.

415.Graham F.L., van der Eb A.J. (1973) A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology, 52, 456-467.

416.Bally M.B., Harvie P., Wong F.M., Kong S., Wasan E.K., Reimer D.L. (1999) Biological barriers to cellular delivery of lipid-based DNA carriers. Adv.Drug Deliv.Rev., 38, 291-315.

417.De Smedt S.C., Remaut K., Lucas B., Braeckmans K., Sanders N.N., Demeester J. (2005) Studying biophysical barriers to DNA delivery by advanced light microscopy.

Adv.Drug Deliv.Rev., 57, 191-210.

418.Roth C.M. (2005) Molecular and cellular barriers limiting the effectiveness of antisense oligonucleotides. Biophys.J., 89, 2286-2295.

419.Ruponen M., Honkakoski P., Ronkko S., Pelkonen J., Tammi M., Urtti A. (2003) Extracellular and intracellular barriers in non-viral gene delivery. J.Control Release, 93, 213-

420.Suh J., Dawson M., Hanes J. (2005) Real-time multiple-particle tracking: applications to drug and gene delivery. Adv.Drug Deliv.Rev., 57, 63-78.

421.Wiethoff C.M., Gill M.L., Koe G.S., Koe J.G., Middaugh C.R. (2002) The structural organization of cationic lipid-DNA complexes. J.Biol.Chem., 277, 44980-44987.

422.Zabner J., Fasbender A.J., Moninger T., Poellinger K.A., Welsh M.J. (1995) Cellular and molecular barriers to gene transfer by a cationic lipid. J.Biol.Chem., 270, 18997-19007.

423.Katsel P.L., O'Connell B., Mizuno T.M., Mobbs C.V., Greenstein R.J. (2000) Liposome mediated gene transfer into GH3 cells, and rat brain, liver and gut: comparison of different polar or aliphatic domains. Int.J.Surg.Investig., 1, 415-429.

424.Montana G., Bondi M.L., Carrotta R., Picone P., Craparo E.F., San Biagio P.L., Giammona G., Di Carlo M. (2007) Employment of cationic solid-lipid nanoparticles as RNA carriers. Bioconjug.Chem., 18, 302-308.

425.Pan X., Guan J., Yoo J.W., Epstein A.J., Lee L.J., Lee R.J. (2008) Cationic lipidcoated magnetic nanoparticles associated with transferrin for gene delivery. Int.J.Pharm., 358, 263-270.

426.Asasutjarit R., Lorenzen S.I., Sirivichayakul S., Ruxrungtham K., Ruktanonchai U., Ritthidej G.C. (2007) Effect of solid lipid nanoparticles formulation compositions on their size, zeta potential and potential for in vitro pHIS-HIV-hugag transfection. Pharm.Res., 24, 1098-1107.

427.Takashima Y., Saito R., Nakajima A., Oda M., Kimura A., Kanazawa T., Okada H. (2007) Spray-drying preparation of microparticles containing cationic PLGA nanospheres as gene carriers for avoiding aggregation of nanospheres. Int.J.Pharm., 343, 262-269.

428.Basarkar A., Devineni D., Palaniappan R., Singh J. (2007) Preparation, characterization, cytotoxicity and transfection efficiency of poly(DL-lactide-co-glycolide) and poly(DLlactic acid) cationic nanoparticles for controlled delivery of plasmid DNA. Int.J.Pharm., 343, 247-254.

429.Zhang Y., Zhang Y., Chen J., Zhang B., Pan Y., Ren L., Zhao J., Luo Y., Zhai D., Wang S., Wang J. (2007) Polybutylcyanoacrylate nanoparticles as novel vectors in cancer gene therapy. Nanomedicine., 3, 144-153.

430.MacDonald R.C., Ashley G.W., Shida M.M., Rakhmanova V.A., Tarahovsky Y.S., Pantazatos D.P., Kennedy M.T., Pozharski E.V., Baker K.A., Jones R.D., Rosenzweig H.S.,

228

Choi K.L., Qiu R., McIntosh T.J. (1999) Physical and biological properties of cationic triesters of phosphatidylcholine. Biophys.J., 77, 2612-2629.

431.MacDonald R.C., Rakhmanova V.A., Choi K.L., Rosenzweig H.S., Lahiri M.K. (1999) O-ethylphosphatidylcholine: A metabolizable cationic phospholipid which is a serumcompatible DNA transfection agent. J.Pharm.Sci., 88, 896-904.

432.Gao X., Huang L. (1991) A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem.Biophys.Res.Commun., 179, 280-285.

433.Farhood H., Bottega R., Epand R.M., Huang L. (1992) Effect of cationic cholesterol derivatives on gene transfer and protein kinase C activity. Biochim.Biophys.Acta, 1111, 239-

434.Nakanishi M. (2003) New strategy in gene transfection by cationic transfection lipids with a cationic cholesterol. Curr.Med.Chem., 10, 1289-1296.

435.Ren T., Zhang G., Liu F., Liu D. (2000) Synthesis and evaluation of vitamin D-based cationic lipids for gene delivery in vitro. Bioorg.Med.Chem.Lett., 10, 891-894.

436.Walker S., Sofia M.J., Kakarla R., Kogan N.A., Wierichs L., Longley C.B., Bruker K., Axelrod H.R., Midha S., Babu S., Kahne D. (1996) Cationic facial amphiphiles: a promising class of transfection agents. Proc.Natl.Acad.Sci.U.S.A, 93, 1585-1590.

437.Kichler A., Leborgne C., Savage P.B., Danos O. (2005) Cationic steroid antibiotics demonstrate DNA delivery properties. J.Control Release, 107, 174-182.

438.Ewert K.K., Evans H.M., Zidovska A., Bouxsein N.F., Ahmad A., Safinya C.R. (2006) A columnar phase of dendritic lipid-based cationic liposome-DNA complexes for gene delivery: hexagonally ordered cylindrical micelles embedded in a DNA honeycomb lattice. J.Am.Chem.Soc., 128, 3998-4006.

439.Maslov M.A., Syicheva E.V., Morozova N.G., Serebrennikova G.A (2000) Cationic amphiphiles of both lipid and nonlipid nature in gene therapy. Russian Chem.Bull., 49, 385-

440.Zhi D., Zhang S., Wang B., Zhao Y., Yang B., Yu S. (2010) Transfection efficiency of cationic lipids with different hydrophobic domains in gene delivery. Bioconjug.Chem., 21, 563-577.

441.Cameron F.H., Moghaddam M.J., Bender V.J., Whittaker R.G., Mott M., Lockett T.J. (1999) A transfection compound series based on a versatile Tris linkage. Biochim.Biophys.Acta, 1417, 37-50.

442.Pinnaduwage P., Schmitt L., Huang L. (1989) Use of a quaternary ammonium detergent in liposome mediated DNA transfection of mouse L-cells. Biochim.Biophys.Acta, 985, 33-37.

443.Tang F., Hughes J.A. (1999) Synthesis of a single-tailed cationic lipid and investigation of its transfection. J.Control Release, 62, 345-358.

444.Wetzer B., Byk G., Frederic M., Airiau M., Blanche F., Pitard B., Scherman D. (2001) Reducible cationic lipids for gene transfer. Biochem.J., 356, 747-756.

445.Byk G., Dubertret C., Escriou V., Frederic M., Jaslin G., Rangara N., Pitard B., Crouzet J., Wils P., Schwartz B., Scherman D. (1998) Synthesis, activity, and structureactivity relationship studies of novel cationic lipids for DNA transfer. J.Med.Chem., 41, 224-

446.Rosenzweig H.S., Rakhmanova V.A., McIntosh T.J., MacDonald R.C. (2000) O-Alkyl dioleoylphosphatidylcholinium compounds: the effect of varying alkyl chain length on their physical properties and in vitro DNA transfection activity. Bioconjug.Chem., 11, 306-313.

447.Byk G., Wetzer B., Frederic M., Dubertret C., Pitard B., Jaslin G., Scherman D. (2000) Reduction-sensitive lipopolyamines as a novel nonviral gene delivery system for modulated release of DNA with improved transgene expression. J.Med.Chem., 43, 4377-4387.

448.Kasireddy K., Ali S.M., Ahmad M.U., Choudhury S., Chien P.Y., Sheikh S., Ahmad I. (2005) Synthesis of cationic cardiolipin analogues. Bioorg.Chem., 33, 345-362.

449.Gaucheron J., Wong T., Wong K.F., Maurer N., Cullis P.R. (2002) Synthesis and properties of novel tetraalkyl cationic lipids. Bioconjug.Chem., 13, 671-675.

450.Bajaj A., Paul B., Indi S.S., Kondaiah P., Bhattacharya S. (2007) Effect of the hydrocarbon chain and polymethylene spacer lengths on gene transfection efficacies of gemini lipids based on aromatic backbone. Bioconjug.Chem., 18, 2144-2158.